Today's Rundown GSK, after pushing past midphase fail, ends development of otilimab in COVID-19 Google taps Headspace executive to lead tech-driven mental health efforts Teva's Austedo, struggling from a pandemic slowdown, needs huge gains to meet 2021 projections One Drop launches Bayer-boosted AI program for preventing heart disease EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies Novavax completes UK filing for COVID-19 vaccine but pushes FDA ask till end of year LifePoint Health to create new 79-hospital company upon close of Kindred Healthcare acquisition NuVasive to launch international VR training program for spine surgery with PrecisionOS Johnson & Johnson inks $297M opioid deal with Texas as national deal faces holdouts Takeda buys out collaborator GammaDelta Therapeutics for solid tumor pipeline Urban Institute: COVID-19 provider relief fund likely to grow past $26.8B as money gets returned Immunai secures $215M for immune system map, fuel more acquisitions Featured Story | By Nick Paul Taylor GlaxoSmithKline is stopping development of otilimab in COVID-19, reacting to the failure of the drug in phase 2 and the progress of its anti-SARS-CoV-2 antibody by pulling the plug on the program. Development of otilimab in rheumatoid arthritis is continuing. read more |
| |
|---|
|
Top Stories By Heather Landi Google is ramping up its focus on mental health and brought former Headspace executive Megan Jones Bell on board to lead its consumer-facing efforts. Bell, former chief strategy and science officer of Headspace, will join Google as its clinical director of consumer and mental health, the tech giant announced Tuesday. read more By Eric Sagonowsky As Teva battles generic pricing pressures and copycats to its multiple sclerosis drug Copaxone, the company has a lot riding on its ability to juice up sales of Austedo and Ajovy. Its top-selling medicine Austedo for tardive dyskinesia is struggling amid the pandemic slowdown, but execs see reasons for optimism in the final quarter of the year. read more By Conor Hale The digital diabetes maven One Drop is taking new steps into the broader healthcare world with an artificial intelligence-powered platform aimed at preventing cardiovascular disease, co-developed with the pharmaceutical giant Bayer. read more By Joseph Keenan EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed. read more By Kyle LaHucik The FDA is no longer Novavax's first choice. The Maryland biotech has instead completed submission of its protein-based COVID-19 vaccine to the U.K.'s regulator and will wait a bit longer before asking the FDA for clearance. read more By Dave Muoio Called ScionHealth, the Louisville-based entity will include 61 of Kindred’s long-term acute care hospitals alongside 18 of LifePoint’s community hospitals. LifePoint's remaining 65 hospitals and other facilities will be combined with Kindred's rehabilitation and behavioral health business. read more By Conor Hale Working with the orthopedic VR surgery developer PrecisionOS, NuVasive aims to deliver a cadaver-less training course built around its X360 system. read more By Eric Sagonowsky Johnson & Johnson and the United States' three top drug distributors already agreed to a national opioid settlement worth $26 billion. But because that deal has yet to be finalized, the pharma giant is moving forward with a separate deal with Texas. read more By Kyle LaHucik Takeda will buy its gamma-delta T-cell therapy partner GammaDelta Therapeutics after the U.K. biotech began its first clinical trial just last month. The two companies initially came together in 2017 under a $100 million R&D agreement. read more By Robert King A new analysis from the Urban Institute found there is $26.8 billion left in a COVID-19 relief fund, and more could be on the way as providers start to return unspent monies. read more By Kyle LaHucik Immunai raised $215 million in a series B, which brings the three-year-old startup's total cash haul to $295 million. The fresh proceeds will help the company build partnerships with biopharmas, expand its team and make more acquisitions. read more | 